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SUMMARY 
The role of plasminogen activator inhibitor-1 (PAI-1) in vascular smooth muscle cell (VSMC) 
apoptosis mediated by plasminogen activation was studied with the use of aortic VSMC 
derived from mice with deficiency of PAI-1 (PAI-1-/-), tissue-type (t-PA-/-) or urokinase-type 
(u-PA-/-) plasminogen activator or from wild-type (WT) mice with corresponding genetic 
background. 
Plasminogen incubated with confluent VSMC was activated in a concentration-dependent and 
saturable manner for all 4 cell types, with maximal activation rates that were comparable for 
WT, u-PA-/- and t-PA-/- cells, but about 2- fold higher for PAI-1-/- cells.  Plasminogen 
activation was impaired by addition of the lysine analogue 6-aminohexanoic acid, and by 
addition of t-PA and u-PA neutralizing antibodies, suggesting that it depends on binding to 
cell surface COOH-terminal lysine residues, and on plasminogen activator activity. 
Morphological alterations consistent with apoptosis were observed much earlier in PAI-1-/- 
than in WT VSMC. Without addition of plasminogen, the apoptotic index was similar for all 4 
cell types, whereas after incubation with physiological plasminogen concentrations, it was 
greater in PAI-1-/- VSMC, as compared to WT, t-PA-/- or u-PA-/- VSMC. Furthermore, the 
apoptotic rate paralleled the release of plasmin. 
Thus, plasmin-mediated apoptosis of VSMC occurs via plasminogen activation by either t-PA 
or u-PA and is impaired by PAI-1. 
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INTRODUCTION 
Vascular smooth muscle cell (VSMC) loss by apoptosis is considered to be a major 
determinant of atherosclerotic plaque vulnerability (1-3), since VSMC can stabilize the plaque 
via synthesis of fibrillar collagen and protease inhibitors. Little is known, however, about the 
mechanisms that trigger VSMC apoptosis. It was suggested that pericellular proteolysis may 
affect cell anchorage leading to apoptosis (anoïkis) (4).  Recent in vitro studies indicate that 
VSMC are able to activate plasminogen into plasmin (5-7), leading to VSMC apoptosis (7), 
suggesting a functional role of the fibrinolytic (plasminogen/plasmin) system. This proteolytic 
system contains an inactive zymogen, plasminogen, that can be activated to the serine 
proteinase plasmin by tissue-type (t-PA) or urokinase-type (u-PA) plasminogen activator. 
Both plasminogen activators are inhibited predominantly by plasminogen activator inhibitor-1 
(PAI-1), whereas plasmin is inhibited mainly by α2-antiplasmin (8). 
Fibrinolytic activity may promote cell migration, regulate growth factor activity (such as 
Transforming Growth Factor-β (TGF-β) (9), and extracellular matrix remodelling, either 
directly (via degradation of adhesive glycoproteins, such as fibronectin (10) or laminin (11) 
by plasmin) or indirectly (via activation of matrix metalloproteinases (8)). 
We have recently shown that ex vivo incubation with plasminogen of aortic tunica media 
isolated from PAI-1 deficient mice resulted in plasminogen activation and VSMC apoptosis, 
which was inhibited by α2-antiplasmin. In vivo, levels of plasmin, active caspase 3 and 
VSMC apoptotic index were significantly higher in atherosclerotic aortas from mice with 
combined ApoE and PAI-1 deficiencies than in those from littermates with single ApoE 
deficiency. A parallel decrease in VSMC density was observed (12).  
The aims of this study were  to investigate the relative roles of t-PA, u-PA and PAI-1 in 
plasminogen activation-mediated VSMC apoptosis with the use of specific gene-deficient 
H
AL author m
anuscript    inserm
-00160754, version 1
 4
cells, and to substantiate a causal link between cellular binding of plasminogen, generation of 
plasmin activity and apoptosis. 
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MATERIALS AND METHODS 
Animals and reagents 
Ten weeks old mice with targeted inactivation of the genes encoding t-PA (t-PA-/-), u-PA (u-
PA-/-), or PAI-1 (PAI-1-/-) and wild-type (WT) mice of the same genetic background (75% 
C57Bl/6 and 25% 129SV) and of either sex were obtained as described elsewhere (13-15). 
For all surgical procedures, mice were anesthetized by intraperitoneal injection of Nembutal 
(60 mg/kg ; Abbott Laboratories, North Chicago, IL, USA). All procedures were approved by 
the University Ethical Committee and were performed in accordance with the guidelines of 
the International Society on Thrombosis and Haemostasis (16). 
Human or murine plasminogen, plasmin, and α2-antiplasmin were obtained as described 
(17,18). Primary monoclonal antibodies used were anti-murine t-PA, u-PA and PAI-1 
(homemade (19)). The chromogenic plasmin substrate pyroGlu-Phe-Lys-pNA (S-2403) was 
purchased from Chromogenix (Antwerp, Belgium). 
Cell culture  
To obtain smooth muscle cells, at least two mice of each genotype were sacrificed, perfused 
with sterile saline, and the aorta was dissected free of the adventitia. The aorta (thoracic and 
upper part of the abdominal aorta) was transferred to DMEM containing 20% heat inactivated 
fetal bovine serum, 2 mM glutamine, 4.5 g/l glucose, 100 U/ml penicillin and 0.1 mg/ml 
streptomycin. The vessel was cut into small fragments (<1 mm3) which were incubated in 6-
well plates coated with collagen (collagen S, type I, at 30 µg/ml in PBS) in DMEM containing 
1x NEAA, 10 ng/ml basic fibroblast growth factor, 20% foetal calf serum, 2 mM glutamine, 
100 U/ml penicillin and 0.1 mg/ml streptomycin, in a humidified CO2-incubator at 37°C (20).  
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Protein assays 
Following plasminogen activation, cells were washed twice with phosphate- buffered saline 
(PBS) and lysed with 1% Triton X-100 in PBS (15 min at 4°C). Samples were centrifuged at 
10, 000 g for 10 min at 4°C, the supernatant was removed by aspiration and stored at -80 °C. 
For zymography of plasminogen activator activity, equal protein amounts were 
electrophoresed on a 12.5% acrylamide gel cast with 1% non fat dry milk and 5 µg/ml human 
plasminogen under nonreducing conditions (21). The gel was washed at room temperature in 
2.5 % Triton X-100 and incubated overnight at 37°C in buffer containing 100 mM glycine at 
pH 8.0. Gels were stained in 0.5 % Coomassie Brilliant Blue R250 and destained in buffer 
containing 45 % ethanol and 10% acetic acid (20). 
Murine plasminogen (22), tPA, u-PA and PAI-1 (19) antigen levels in conditioned media and 
cell lysates were measured by ELISA.  
For plasminogen activation assays, VSMC cultured in 96 well plates were starved of serum 
for 24 h. Cells were then incubated at 37°C with plasminogen at varying concentrations (0-10 
µM) supplemented with inhibitors when indicated (preincubation with 20 mM 6-
aminohexanoic acid (6-AHA) for 30 minutes or with 200 µg/ml rabbit polyclonal antibodies 
neutralizing t-PA and/or u-PA for 2 hours; addition of 1 µM α2-antiplasmin). Kinetics of 
plasmin generation were monitored from the rate of p-nitroaniline release from the 
chromogenic substrate S-2403 (0.1 mM final concentration). The change in absorbance at 405 
nm as a function of time (which was linear up to 12 h) was monitored using a multiwell plate 
reader (ELX808, Bio-Tek instruments). In other experiments, plasmin generation was 
monitored in the conditioned media of cultured VSMC incubated for 4 to 24 hours with 
varying concentrations of plasminogen and inhibitors as indicated, using S-2403 at 0.2 mM 
final concentration. 
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Detection of cell survival and apoptosis 
After 4 to 72 hours of incubation with plasminogen and/or other reagents (cf. above), VSMC 
were washed with PBS and cell survival and apoptosis were determined as follows.  
Cell detachment assay. VSMC were incubated for 1 hour at 37°C with 0.5 mg/ml of the 
tetrazolium salt, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma, 
Steinheim, Germany),  in PBS. Detached cells were discarded; residual living adherent cells 
formed formazan cristals that were dissolved in dimethyl sulfoxide and colorimetrically 
detected at 550 nm using a multiwell plate reader. Absorbance readings are proportional to the 
number of living cells (23). 
TUNEL and DAPI staining. To visualize DNA fragmentation, cells grown on 4-well slide 
chambers (Lab-Tek®, Nalge Nunc International Corp, Naperville, IL, USA) were submitted 
to terminal transferase dUTP Nick End Labeling (TUNEL) (Roche Molecular Biochemicals, 
Mannheim, Germany), and 4’,6-diamidino-2-phenylindole (DAPI) nuclear counter-staining, 
the latter being included in the mounting solution (Vectashield, Vector Laboratories, 
Burlingame, CA, USA) according to the manufacturer’s instructions. A positive control 
(1μg/ml DNAse I treatment of the cells for 10 min after permeabilization) and a negative 
control (without terminal transferase) were included in each experiment.  
Quantification of DNA fragments. Histone-associated DNA fragments were quantified using a 
photometric enzyme immunoassay (Cell Death Detection ELISA PLUS, Roche Molecular 
Biochemicals, Mannheim, Germany) (24), following the manufacturer’s procedure.  
Statistical analysis 
The statistics were performed with the Statview 5.0 software. Results are expressed as mean ± 
SEM. Comparisons were made by one-way analysis of variance with Scheffe’s F test, or 
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Wilcoxon signed ranks, or Mann-Whitney U-test, as appropriate. Correlations were assessed 
by Spearman’s rank correlation test. Statistical significance was set at P < 0.05. 
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RESULTS 
Activation of plasminogen by murine vascular smooth muscle cells in primary culture 
Zymography of cell lysates on casein-containing gels revealed u-PA activity in WT, t-PA-/-, 
and PAI-1-/- VSMC (Figure 1); u-PA antigen levels in conditioned media and cell lysates 
were, however, below the detection limit (0.31 ng/ml) of the ELISA. t-PA activity was 
detected only in PAI-1-/- VSMC (Figure 1), while t-PA antigen levels in 72 h conditioned 
media were eightfold higher for PAI-1-/- VSMC, as compared to WT or u-PA-/- cells (both P < 
0.0001), and undetectable for t-PA-/- VSMC (Table 1). PAI-1 antigen levels in 72 h 
conditioned media were comparable for WT, u-PA-/- and t-PA-/- VSMC and undetectable for 
PAI-1-/- VSMC (Table 2) ; none of the cell lines produced detectable amounts of plasminogen 
(detection limit of the ELISA: 0.16 ng/ml). 
Plasminogen incubated with confluent VSMC was activated in a concentration-dependent and 
saturable manner for all 4 cell types (Figure 2a), with maximal activation rates of 2.74  ± 0.1 x 
10-3 A405nm.min-1 for WT cells, 2.45 ± 0.1 x 10-3 A405nm.min-1 for u-PA-/- cells, 2.63 ± 0.1 x 10-
3 A405nm.min-1 for t-PA-/- cells, and 4.7 ± 0.1 x 10-3 A405nm.min-1 for PAI-1-/- VSMC (n=4; P < 
0.001 vs. the other cell types). 
Plasminogen activation occurred at the cell surface and depended on its binding to COOH-
terminal lysine residues as indicated by the inhibition of plasmin formation by addition of 20 
mM of the lysine analogue 6-AHA to WT VSMC (generated plasmin reduced to 49 ± 6.5 % 
(n= 3) for cells incubated with 1.25 µM plasminogen for 24 h (p< 0.04), and to 29 ± 2.3% (n= 
6) for cells incubated with 625 nM plasminogen for 72 h (P < 0.0001)). It also depended on 
plasminogen activator activity, as indicated by its inhibition (to 17 ± 8.4 %, P < 0.04 or to 66 
± 7.6 %, P < 0.01 respectively) after preincubation of WT VSMC with 200 µg/ml antibodies 
neutralizing t-PA and u-PA. Following plasminogen activation, plasmin was released in the 
conditioned media (with a linear correlation between released plasmin and the plasminogen 
H
AL author m
anuscript    inserm
-00160754, version 1
 10
concentration added, r = 0.99), where it was specifically inhibited by addition of excess α2-
antiplasmin (residual plasmin activity of 16 ± 2.2 %, P < 0.04 or 4 ± 0.5 %, P < 0.0001 vs. 
control cells incubated with 1.25 µM plasminogen for 24h or with 625 nM plasminogen for 
72h). 
Plasmin-mediated vascular smooth muscle cell apoptosis 
Exposure of WT, t-PA-/-, u-PA-/- or PAI-1-/- VSMC to plasminogen (1.25 to 10 µM) for 72 h 
was associated with a concentration-dependent decrease in the number of adherent viable 
cells, as assessed by the MTT test (not shown). A 50% reduction was obtained at a 
plasminogen concentration of 380 nM for PAI-1-/- VSMC, as compared to about 1.1 µM for 
WT, u-PA-/- and t-PA-/- VSMC. Following incubation with plasminogen, morphological 
alterations, reminiscent of apoptosis (including cell shrinkage and nuclear condensation) were 
observed in VSMC of all genotypes (Figure 2 b-e, shows representative photographs for WT 
cells). This process occurred much faster in PAI-1-/- (Figure 2 f-i) as compared to WT VSMC 
and depended on plasminogen binding to COOH-terminal lysine residues (as indicated by the 
inhibition with the lysine analogue 6-AHA: not shown), and on plasminogen activation, as 
shown by the inhibition by α2-antiplasmin (Figure 2 e, i). TUNEL reaction revealed parallel 
DNA fragmentation, indicating a proapoptotic effect, mediated by plasminogen activation and 
abolished by α2-antiplasmin (Figure 3A, a to f). Quantification of histone-associated DNA 
fragments by ELISA revealed an increase in the apoptotic rate of WT VSMC incubated with 
1.25 µM plasminogen for up to 72 h (Figure 3B), the proapoptotic effect being detectable as 
early as after 4 h (Figure 3 C). This effect depended on plasminogen binding to 
carboxyterminal lysine residues (as indicated by the inhibition of the apoptotic effect by the 
lysine analogue 6-AHA), and on plasmin activity, as indicated by the inhibition with α2-
antiplasmin (Figure 3A, f and 3B). Moreover, DNA fragmentation on the one hand, and cell 
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viability (as assessed by the MTT test) on the other hand, strongly correlated with plasmin 
levels (Rho= 0.933, P= 0.009, and Rho= -0.745, P < 0.04, respectively). 
Comparison of the internucleosomal DNA fragmentation levels at various time points (4 to 24 
h) and different plasminogen concentrations, revealed similar baseline (without addition of 
plasminogen) apoptotic levels in all cell types (not shown). After incubation with 
plasminogen (Figure 3C-D), the apoptotic index was greater in PAI-1-/- VSMC, as compared 
to WT, t-PA-/- or u-PA-/- VSMC (which were not different from each other). The apoptotic 
rate paralleled plasmin release (Figures 3D-E for incubation with 0.625 µM plasminogen for 4 
h). 
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DISCUSSION 
Cell death by apoptosis is considered to be a major determinant of atherosclerotic plaque 
vulnerability (1-3). Conflicting in vitro data have been reported on a potential role of the 
fibrinolytic (plasminogen/plasmin) system in VSMC apoptosis. Thus, Meilhac et al. (7) 
reported plasminogen activation-induced cell detachment and apoptosis in primary cultured 
rat VSMC expressing t-PA, whereas cultured human VSMC expressing u-PA only displayed 
loss of adhesion after very prolonged exposure (up to 12 days) (6). In addition, in the absence 
of plasminogen, PAI-1 was reported to have a proapoptotic effect on VSMC (25), whereas an 
antiapoptotic effect was reported on PC-3 and HL-60 cancer cells (26). Our in vitro 
experiments with primary cultured aortic murine VSMC in the presence of plasminogen, 
revealed VSMC apoptosis associated with plasmin generation, regardless of the type of 
plasminogen activator involved. The requirement for plasmin activity was confirmed in 
subsequent studies with the use of an active site variant of plasminogen that generates inactive 
plasmin after cleavage by plasminogen activators (unpublished data).  Our in vitro data 
furthermore confirms that plasminogen activation by VSMC requires binding of plasminogen 
to cell surface exposed COOH-terminal lysine residues.  This was also confirmed in other 
studies showing abolished binding of plasminogen and plasmin generation following 
treatment of cells with TAFI, removing COOH-terminal lysines (unpublished data).  VSMC 
deficient in t-PA or u-PA activated plasminogen in a comparable manner as WT cells, 
expressing only u-PA, whereas PAI-1-/- VSMC that expressed both u-PA and t-PA displayed 
an about 2-fold higher maximal activation rate.  Because for PAI-1-/- cells 2 active enzymes 
are present (u-PA and t-PA), and because an effect of additional exposure of plasminogen-
binding sites and/or secretion of plasminogen activators during the experimental period can 
not be excluded, these data can not be used to derive meaningful kinetic parameters.  They do 
confirm, however, that t-PA and u-PA can both induce comparable plasmin generation.  In 
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these activation experiments, the amount of plasmin generated corresponded to only a few 
percent (<8%) of the plasminogen added (data not shown).  To mimic physiological systems, 
we have previously performed similar experiments with addition of α2-antiplasmin (7); when 
low α2-antiplasmin concentrations are used, these data showed that secreted plasmin is 
inhibited, whereas plasmin generated at the cell surface is protected and can still induce cell 
detachment and apoptosis. Our in vitro studies focussed on cell-associated plasminogen 
activation in the absence of α2-antiplasmin may thus be relevant.  In contrast, higher α2-
antiplasmin concentrations such as those we used in the present study are able to efficiently 
inhibit plasmin apoptotic effects (7), presumably because of an inhibition of plasmin 
amplification generation. 
In the absence of plasminogen, similar apoptotic rates were observed in WT and PAI-1-/- 
VSMC, suggesting that PAI-1 does not directly induce apoptosis. This is in agreement with 
the finding that, with endothelial cells, addition of PAI-1 inhibited plasminogen activation 
induced gel contraction and capillary regression, whereas anti-PAI-1 antibodies potentiated 
these processes (27). Moreover, we recently showed that fibroblasts in two or three 
dimensional culture systems became resistant to plasminogen activation-induced cell 
detachment and apoptosis when transfected either with PAI-1 or Protease-Nexin-1 (a serpin 
that inhibits plasminogen activators and plasmin); both inhibitors inhibited plasminogen 
activation at the cell surface, and subsequent pericellular proteolysis (28). 
The extracellular pathway leading to plasmin induced apoptosis has recently been described 
(4,7), and concerns various cell types, including retinal ganglion cells (29), endothelial cells 
(27,30), fibroblasts (28), and VSMC (7). Bauriedel et al. (3) observed that apoptotic VSMC 
detached from the surrounding extracellular matrix in human atherosclerotic plaques, and 
Meilhac et al. (7) suggested that the disruption of extracellular matrix-cell signalling pathways 
could be involved. Indeed, in primary cultured rat VSMC, cleavage of fibronectin parallelled 
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plasminogen activation, and VSMC detachment and apoptosis; in addition, proMMP 
activation by plasmin was observed, but VSMC apoptosis was not blocked by MMP 
inhibitors (7). Plasmin may also activate latent growth factors such as latent TGFP-β, which 
may induce VSMC apoptosis (31). 
In the presence of plasminogen, the VSMC apoptotic index parallels plasmin formation, and 
addition of α2-antiplasmin protects against apoptosis, supporting the concept that plasmin 
activity is crucial. Our data with plasminogen activator neutralizing antisera further confirm 
that plasminogen activator activity is required, which is consistent with the finding that PAI-1 
impairs apoptosis. 
Our data are thus relevant to understand the role of the fibrinolytic system in VSMC 
apoptosis, given the facts that they 1) demonstrate that plasmin induces apoptosis regardless 
of the type of plasminogen activator; 2) confirm that plasmin activity is required for apoptosis 
and involves cellular binding through its lysine-binding sites; and 3) show that PAI-1 can 
impair plasminogen activation-mediated VSMC apoptosis. 
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LEGENDS TO THE FIGURES 
Figure 1.  Plasminogen activator activity in VSMC lysates.  
Lysates of wild-type (WT), t-PA-/-, u-PA-/- and PAI-1-/- murine VSMC were subjected to 
zymography on casein-containing gels. Caseinolytic activity resulting from plasminogen 
activation by u-PA or t-PA was detected as lysis areas after overnight incubation at 37°C.  
Figure 2. Morphological alterations of VSMC following plasminogen activation. 
Plasminogen (Pg) activation rate by confluent, 24 hours serum-starved, WT (z), t-PA-/- (), 
u-PA-/- (S), and PAI-1-/- (T) VSMC are shown (panel a). The rate of plasmin generation was 
monitored over 12 hours and expressed as mA405nm/min. 
Confluent WT (panels b - e) and PAI-1-/- (panels f - i) VSMC, 24 hours serum-starved, were 
incubated without (Pg 0 : panels b and f) and with plasminogen (Pg 1.25 µM, panels c - e and 
g -i) for 72 (WT) or 3.5 (PAI-1-/-) hours, respectively. In panels e and i, 1 µM α2-antiplasmin 
(AP) was added. The scale bars correspond to 100 µm. Panels d and h are magnifications 
(scale bar 20 µm) taken from panels c and g, respectively. 
Figure 3: Plasmin-mediated VSMC apoptosis. 
A. After 72 hours incubation without plasminogen (a, d), with 1.25 µM plasminogen (b, 
e) or with a mixture of 1.25 µM and plasminogen and 1 µM α2-antiplasmin (c, f), 
remaining WT VSMC were fixed and stained with DAPI (upper panels) or TUNEL 
(lower panels). The scale bars correspond to 100 µm. 
B.  WT VSMC apoptosis was assessed by quantification of DNA fragmentation, after 72 
hours incubation without (Pg 0) or with 1.25 µM plasminogen (Pg), without or with pre-
incubation for 30 minutes with 6-AHA (20 mM), or addition of α2-antiplasmin (AP, 1 
µM). Data, expressed as A405nm.10-3.min-1 correspond to the amount of fragmented 
H
AL author m
anuscript    inserm
-00160754, version 1
 20
nucleosomes, and are mean ± SEM, representative of two experiments performed 
independently in triplicate wells *P < 0.05 vs. Pg 0, and ° P < 0.05 vs. Pg.  
C-D. Plasminogen-induced apoptotic index following incubation of 24 hours serum starved 
confluent VSMC with 0.625 µM plasminogen for 4  hours (C) or with 1.25 µM plasminogen 
for 24  hours (D) is expressed as the ratio: 100 x (DNA fragments measured in stimulated 
cells/corresponding control cells).  ° P<0.01 and * P<0.02 vs. PAI-1 -/- VSMC. 
E. Plasmin activity in the conditioned media from cells described in panel C is expressed in 
arbitrary units (A405nm.10-3.min-1) normalized to the number of corresponding control cells, as 
assessed by the MTT test. 
Data are mean ± SEM and are representative of two experiments performed independently in 
triplicate wells. ° P<0.0001 vs. PAI-1 -/- cells. 
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Table 1. t-PA levels in VSMC conditioned media as a function of time.   
Murine t-PA levels in conditioned media (12 to 72 hours) from primary cultures of VSMC 
derived from WT, t-PA-/-, u-PA-/- and PAI-1-/- mice were measured by ELISA. 
 t-PA (ng/ml) 
 12h 24h 48h 72h 
WT 4.5 ± 0.6 5.2 ± 0.5 2.4 ± 0.5 2.3 ± 0.5 
t-PA-/- N.D. N.D. N.D. N.D. 
u-PA-/- 1.1 ± 0.1 1.3 ± 0.1 1.2 ± 0.3 1.5 ± 0.4 
PAI-1-/- 12.1 ± 1.5 14.7 ± 1.7 18.7 ± 1.8 18.6 ± 1.1 
Data are expressed in ng/ml per 106 cells, and are mean ± SEM of 4 experiments. N.D., not 
detectable. 
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Table 2. PAI-1 levels in VSMC conditioned media as a function of time.   
Murine PAI-1 levels in conditioned media (12 to 72 hours) from primary cultures of VSMC 
derived from WT, t-PA-/-, u-PA-/- and PAI-1-/- mice were measured by ELISA. 
 PAI-1 (ng/ml) 
 12h 24h 48h 72h 
WT 1186 ± 49 1868 ± 88 1646 ± 330 2788 ± 389 
t-PA-/- 635 ± 68 998 ± 63 1770 ± 233 3190 ± 175 
u-PA-/- 850 ± 68 1223 ± 184 1989 ± 123 2301± 209 
PAI-1-/- N.D. N.D. N.D. N.D. 
Data are expressed in ng/ml per 106 cells, and are mean ± SEM of 4 experiments. N.D., not 
detectable. 
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